149 related articles for article (PubMed ID: 1856935)
1. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
Decensi AU; Boccardo F; Guarneri D; Positano N; Paoletti MC; Costantini M; Martorana G; Giuliani L
J Urol; 1991 Aug; 146(2):377-81. PubMed ID: 1856935
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP).
Decensi A; Guarneri D; Paoletti MC; Lalanne JM; Merlo F; Boccardo F
Eur J Cancer; 1991; 27(9):1100-4. PubMed ID: 1835617
[TBL] [Abstract][Full Text] [Related]
3. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
[TBL] [Abstract][Full Text] [Related]
4. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
5. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
Boccon-Gibod L
Eur Urol; 1998; 33(2):159-64. PubMed ID: 9519357
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
[TBL] [Abstract][Full Text] [Related]
7. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
Janknegt RA
Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
[TBL] [Abstract][Full Text] [Related]
8. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Kassouf W; Tanguay S; Aprikian AG
J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
[TBL] [Abstract][Full Text] [Related]
9. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
Du Plessis DJ
Urology; 1991; 37(2 Suppl):20-4. PubMed ID: 1992599
[TBL] [Abstract][Full Text] [Related]
10. Nilutamide: possible utility as a second-line hormonal agent.
Desai A; Stadler WM; Vogelzang NJ
Urology; 2001 Dec; 58(6):1016-20. PubMed ID: 11744479
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
Mahler C; Verhelst J; Denis L
Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
[TBL] [Abstract][Full Text] [Related]
12. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
[TBL] [Abstract][Full Text] [Related]
13. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
Janknegt RA; Abbou CC; Bartoletti R; Bernstein-Hahn L; Bracken B; Brisset JM; Da Silva FC; Chisholm G; Crawford ED; Debruyne FM
J Urol; 1993 Jan; 149(1):77-82; discussion 83. PubMed ID: 7678043
[TBL] [Abstract][Full Text] [Related]
14. The role of antiandrogen monotherapy in the treatment of prostate cancer.
Anderson J
BJU Int; 2003 Mar; 91(5):455-61. PubMed ID: 12603397
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
Dijkman GA; Janknegt RA; De Reijke TM; Debruyne FM
J Urol; 1997 Jul; 158(1):160-3. PubMed ID: 9186345
[TBL] [Abstract][Full Text] [Related]
16. Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.
Pavone-Macaluso M; Cacciatore M; Daricello G; Pavone C; Serretta V
Ann N Y Acad Sci; 1990; 595():328-33. PubMed ID: 2375611
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
[TBL] [Abstract][Full Text] [Related]
19. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
Harris MG; Coleman SG; Faulds D; Chrisp P
Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
[TBL] [Abstract][Full Text] [Related]
20. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Schröder FH
Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
